Safety and protective efficacy of intramuscular vaccination with a live aroA derivative of Pasteurella multocida B:2 against experimental hemorrhagic septicemia in calves.
Three groups of five calves, namely, V1, V2, and V3, were immunized intramuscularly at 4 and 8 weeks of age with ca. 10(9), 10(8), and 10(7) CFU, respectively, of a derivative of Pasteurella multocida B:2 wild-type strain 85020 containing a deletion in the aroA gene (strain JRMT12). The first and second vaccinations resulted in significantly (P < 0.01) higher rectal temperature responses in groups V1 and V2 than in group V3. Serum immunoglobulin M (IgM) and IgG titers did not increase in any group until after the second vaccination and were then significantly higher in groups V1 and V2 than in group V3 (P = 0.001 for both IgM and IgG). All vaccinated groups and three unvaccinated challenge control calves (group CC) were injected subcutaneously at 10 weeks of age with ca. 10(7) CFU of strain 85020. Vaccinated calves survived the challenge, but two CC animals developed clinical disease and were killed for humane reasons. After challenge, mean serum amyloid A concentrations were significantly higher (P < 0.001) in the CC group than in the vaccinated groups. Postmortem examination revealed that calves in the CC group showed the most extensive range of bacteriologically positive tissues and gross and histopathological lesions. Overall, a clear dose-dependent response was present, with those receiving a higher vaccine dose being less affected clinically, bacteriologically, and pathologically by the wild-type challenge. The V2 treatment appeared to give the best combination of high immune response, protection, and safety.
Dagleish
Mark P
MP
Moredun Research Institute, International Research Centre, Pentlands Science Park, Bush Loan, Penicuik, Midlothian, United Kingdom.
Hodgson
J Christopher
JC
Ataei
Saeed
S
Finucane
Anna
A
Finlayson
Jeanie
J
Sales
Jill
J
Parton
Roger
R
Coote
John G
JG
D051229:3-Phosphoshikimate 1-Carboxyvinyltransferase / Q000378:metabolism; D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology* / Q000494:pharmacology; D002417:Cattle; D002418:Cattle Diseases / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control; D006483:Hemorrhagic Septicemia / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D007273:Injections, Intramuscular; D010326:Pasteurella Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D016979:Pasteurella multocida / Q000276:immunology* / Q000302:isolation & purification; D000685:Serum Amyloid A Protein / Q000276:immunology* / Q000378:metabolism; D014613:Vaccines, Attenuated / Q000276:immunology / Q000494:pharmacology
D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D000685:Serum Amyloid A Protein; D014613:Vaccines, Attenuated; D051229:3-Phosphoshikimate 1-Carboxyvinyltransferase